Ipsen Achieves Outstanding Recognition for Operational Excellence
Ipsen has achieved a remarkable milestone by receiving its second Shingo Prize, an accolade that symbolizes operational excellence. This recognition underscores Ipsen's commitment to quality and efficiency in its production processes.
Significance of the Shingo Prize
The Shingo Prize is regarded as a benchmark for operational excellence, awarded only to a select few companies that demonstrate a robust culture of continuous improvement. Founded in 1988, the prize evaluates the degree to which an organization embraces core principles integral to sustainable success.
Company’s Journey to Success
Ipsen's first Shingo Prize was awarded to its production facility in Signes, France in 2020. The recent accolade given to the Dublin facility highlights Ipsen's adherence to rigorous operational standards and its focus on enhancing patient care through efficient manufacturing.
Impact on Employees and Operations
Employing nearly 200 individuals, the Dublin site plays a critical role in producing active pharmaceutical ingredients for two of Ipsen's therapeutics. The recognition has not only validated the hard work of the staff but has also fortified a culture of precision and dedication within the workforce.
Voices from Leadership
“It’s truly an honor to receive this second Shingo Prize,” expressed Aidan Murphy, Executive Vice-President and Head of Technical Operations at Ipsen. He emphasized that the Shingo mindset fosters an environment where every employee understands their contribution to the organization’s strategic goals, paving the way for ongoing improvement.
Paul Maginn, head of Excellence Enterprise and Manufacturing Science & Technology, highlighted the importance of his team’s efforts. “The Shingo Prize reflects the energy, dedication, and commitment of each person to embedding the Shingo Model™ across the organization,” Maginn remarked.
About the Dublin Facility
Bénédicte Verley Hudry, Head of the Dublin site, noted the positive experience during the assessment process, commending the team’s dedication to the Shingo principles. These principles advocate for authentic engagement and dedication, which the Dublin team exemplified remarkably.
About Ipsen
Ipsen is a leading global biopharmaceutical company committed to developing transformative medicines across various therapeutic areas, including Oncology, Rare Disease, and Neuroscience. With nearly a century of experience in drug development, Ipsen operates global hubs in critical locations and strives to improve patient outcomes in over 80 countries.
Commitment to Innovation
The company's pipeline benefits from external collaborations, harnessing innovation to tap into new treatments and therapies. This robust network aims to ensure accessibility and availability of critical medications for patients, reinforcing Ipsen’s mission to enhance health and well-being worldwide.
Frequently Asked Questions
What is the Shingo Prize?
The Shingo Prize is an award recognizing operational excellence and a commitment to continuous improvement across various sectors.
How many Shingo Prizes has Ipsen received?
Ipsen has received two Shingo Prizes, one for its facility in Signes, France, and the latest for its site in Dublin, Ireland.
What is the focus of Ipsen as a biopharmaceutical company?
Ipsen focuses on developing transformative medicines in therapeutic areas such as Oncology, Rare Disease, and Neuroscience.
How does the Shingo Prize impact Ipsen's operations?
The Shingo Prize encourages a culture of continuous improvement and operational efficiency, motivating employees to align their work with the company’s strategy.
Where is Ipsen headquartered?
While Ipsen operates globally, its headquarters is located in Paris, where it spearheads various initiatives in drug development and patient care.
